The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer

Meng, Shangsen1; Li, Ming2,3; Qin, Le2; Lv, Jiang2,4; Wu, Di2; Zheng, Diwei2; Jia, Heng2,5,6; Chen, Dongmei2; Wu, Qiting2; Long, Youguo2; Tang, Zhaoyang7; Tang, Yanlai8; Yang, Lihua9; Yao, Yao2; Luo, Xuequn8; Li, Peng1,2,4,10,11

2023-08-01

10.1016/j.intimp.2023.110402

INTERNATIONAL IMMUNOPHARMACOLOGY   影响因子和分区

1567-5769

1878-1705

Colorectal cancer is globally ranked second in both incidence and mortality rate. It usually develops during the middle or late stages of diagnosis, and is characterized by easy metastasis, poor prognosis, and a significant decline in postoperative quality of life. ROR1 is an excellent oncoembryonic antigen in numerous immunotherapy treatments for tumors. Additionally, it is overexpressed in colorectal cancer. To fill the void in CRC treatment with ROR1 as a target of CAR-T immunotherapy, we designed and prepared antiROR1-CART. This third-generation CAR-T cell can effectively inhibit the growth of colorectal cancer in vitro and in vivo.

ROR1 CAR-T CRC Immunotherapy

SCI

英语

其他

National Key Research and Develop- ment Plan["2021YFE0202800","81972672","82202031"] ; National Key Research and Development Plan["2021YFE0202800","81972672","82202031"] ; Guangdong Basic and Applied Basic Research Foundation[2020B1212060052] ; Science and Technology Program of Guangzhou, China[202002020083] ; Guangzhou Medical University High-level University Construction Research Startup Fund[B195002004013] ; University Grants Committee/Research Grants Council[AoE/M-401/20] ; Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Diseases[2019B121205010]

Immunology ; Pharmacology & Pharmacy

Immunology ; Pharmacology & Pharmacy

WOS:001019684200001

ELSEVIER

PHARMACOLOGY & TOXICOLOGY

Web of Science

1.Univ Sci & Technol China, Sch Life Sci, Div Life Sci & Med, Hefei 230027, Peoples R China
2.Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, China New Zealand Joint Lab Biomed & Hlth, State Key Lab Resp Dis,Guangdong Prov Key Lab Stem, Guangzhou, Peoples R China
3.Anhui Univ, Inst Phys Sci & Informat Technol, Dept Hlth Sci, Hefei, Peoples R China
4.Guangzhou Med Univ, Affiliated Hosp 5, Guangdong Higher Educ Inst, Key Lab Biol Targeting Diag Therapy & Rehabil, Guangzhou, Peoples R China
5.Southern Univ Sci & Technol, Sch Sci, Dept Chem, Shenzhen 518055, Peoples R China
6.Southern Univ Sci & Technol, Sch Sci, Res Ctr Chem Biol & Om Anal, Shenzhen 518055, Peoples R China
7.Guangdong Zhaotai Vivo Biomed Co Ltd, Guangzhou 510700, Peoples R China
8.Sun Yat Sen Univ, Affiliated Hosp 1, Dept Paediat, Guangzhou 510080, Guangdong, Peoples R China
9.Southern China Med Univ, Zhujiang Hosp, Dept Paediat, Guangzhou 510280, Guangdong, Peoples R China
10.Chinese Univ Hong Kong CUHK, Fac Med, Dept Surg, Hong Kong, Peoples R China
11.Chinese Acad Sci, Hong Kong Inst Sci & Innovat, Ctr Regenerat Med & Hlth, Hong Kong, Peoples R China

Meng, Shangsen,Li, Ming,Qin, Le,et al. The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer[J]. INTERNATIONAL IMMUNOPHARMACOLOGY,2023,121.

Meng, Shangsen.,Li, Ming.,Qin, Le.,Lv, Jiang.,Wu, Di.,...&Li, Peng.(2023).The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.INTERNATIONAL IMMUNOPHARMACOLOGY,121.

Meng, Shangsen,et al."The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer".INTERNATIONAL IMMUNOPHARMACOLOGY 121(2023).